The protective effect of berberine against neuronal damage by inhibiting matrix metalloproteinase-9 and laminin degradation in experimental autoimmune encephalomyelitis

Neurological Research

Volumn 35, Issue 4, 2013, Pages 360-368

  Jiang, Ying ^a   Wu, Aiming ^a   Zhu, Cansheng ^a   Pi, Rongbiao ^a   Chen, Shaoqiong ^a   Liu, Yingying ^a   Ma, Lili ^a   Zhu, Dongliang ^a   Chen, Xiaohong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Berberine; Experimental autoimmune encephalomyelitis; Laminin; Matrix metalloproteinase; Neuroprotection

Indexed keywords

BERBERINE; GELATIN; GELATINASE; GELATINASE A; GELATINASE B; LAMININ; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEEDING; FEMALE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE INJURY; NEUROPROTECTION; NICK END LABELING; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SCORING SYSTEM; ZYMOGRAPHY;

ANIMALS; BERBERINE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LAMININ; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 84875457035     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000156     Document Type: Article

References (71)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938-52.
2. Trapp BD, Peterson J, Ransohoff RM, Rudick RA, Mork S, Bo L. Axonal transaction in the lesions of multiple sclerosis. N Engl J Med. 2004;388:278-85.
3. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247-69.
4. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120:393-9.
5. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinating lesions. Am J Pathol. 2000;157:267-76.
6. Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol. 2007;62:314-26.
7. Lassmann H. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp Neurol. 2010;225:2-8.
8. Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. Exp Neurol. 2010;225:9-17.
9. Ikram M. A review on the chemical and pharmacological aspects of genus Berberis. Planta Med. 1975;28:353-8.
10. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004;203:127-37.
11. Peng PL, Hsieh YS, Wang CJ, Hsu JL, Chou FP. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicol Appl Pharmacol. 2006;214:8-15.
12. Tang J, Feng YB, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis Rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol. 2009;126:5-17.
13. Chen FL, Yang ZH, Liu Y, Li LX, Liang WC, Wang XC, et al. Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine. 2008;33:331-7.
14. Hwang JM, Kuo HC, Tseng TH, Liu JY, Chu CY. Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol. 2006;80:62-73.
15. Yoo KY, Hwang IK, Lim BO, Kang TC, Kim DW, Kim SM, et al. Berberry extract reduces neuronal damage and N-methyl-D-aspartate receptor 1 immunoreactivity in the gerbil hippo-campus after transient forebrain ischemia. Biol Pharm Bull. 2006;29:623-8.
16. Zhou XQ, Zeng XN, Kong H, Sun XL. Neuroprotective effects of berberine on stroke models in vitro and in vivo. Neurosci Lett. 2008;447:31-6.
17. Hong JS, Chu YK, Lee H, Ahn BH, Park JH, Kim MJ, et al. Effects of berberine on hippocampal neuronal damage and matrix metalloproteinase-9 activity following transient global cerebral ischemia. J Neurosci Res. 2012;90:489-97.
18. Wu J, Jin GZ. Tetrahydroberberine blocks membrane Kz channels underlying its inhibition of intracellular message-mediated outward currents in acutely dissociated CA1 neurons from rat hippocampus. Brain Res. 1997;775:214-8.
19. Opdenakker G, van den Steen PE, van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001;22:571-9.
20. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2:502-11.
21. Opdenakker G, van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol Today. 1994;15:103-7.
22. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol. 2003;136:46-53.
23. Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. 1997;6:590-8.
24. Dubois B, Masure S, Hurtenbach U, Paemen L, Heremans H, van den Oord J, et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest. 1999;104:1507-15.
25. Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol. 1996;8:618-24.
26. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, et al. S-Nitrosylation of matrix metalloproteinases: signaling path-way to neuronal cell death. Science. 2002;297:1186-90.
27. Oki T, Takahashi S, Kuwabara S, Yoshiyama Y, Mori M, Hattori T, et al. Increased ability of peripheral blood lymphocytes to degrade laminin in multiple sclerosis. J Neurol Sci. 2004;222:7-11.
28. Sixt M, Engelhardt B, Pausch F, Hallmann R, Wendler O, Sorokin LM. Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis. J Cell Biol. 2001;153:933-46.
29. van Horssen J, Bo L, Vos CM, Virtanen I, de Vries HE. Basement membrane proteins in multiple sclerosis-associated inflammatory cuffs: potential role in influx and transport of leukocytes. J Neuropathol Exp Neurol. 2005;64:722-29.
30. Wu C, Ivars F, Anderson P, Hallmann R, Vestweber D, Nilsson P, et al. Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med. 2009;15:519-27.
31. Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M, et al. Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS One. 2010;5:e13489.
32. Chen XH, Hu XQ, Zou Y, Pi RP, Liu M, Wang T, et al. Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. J Neuroimmunol. 2009;210:22-9.
33. Lee H, Park JW, Kim SP, Lo EH, Lee SR. Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia. Neurobiol Dis. 2009;34:189-98.
34. Lee SR, Tsuji K, Lee SR, Lo EH. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci. 2004;24:671-8.
35. Qin X, Guo BT, Wan B, Fang L, Lu L, Wu L, et al. Regulation of Th1 and Th17 cell differentiation and amelioration of experimental autoimmune encephalomyelitis by natural pro-duct compound berberine. J Immunol. 2010;185:1855-63.
36. Penkowa M, Hidalgo J. Metallothionein treatment reduces proinflammatory cytokines IL-6 and TNF-alpha and apoptotic cell death during experimental autoimmune encephalomyelitis (EAE). Exp Neurol. 2001;170:1-14.
37. Meyer R, Weissert R, Diem R, Storch MK, de Graaf KL, Kramer B, et al. Acute neuronal apoptosis in a rat model of multiple sclerosis. J Neurosci. 2001;21:6214-20.
38. Guyton MK, Sribnick EA, Ray SK, Banik NL. A role for calpain in optic neuritis. Ann N Y Acad Sci. 2005;1053:48-54.
39. Guyton MK, Wingrave JM, Yallapragada AV, Wilford GG, Sribnick EA, Matzelle DD, et al. Upregulation of calpain correlates with increased neurodegeneration in acute experimental autoimmune encephalomyelitis. J Neurosci Res. 2005;81:53-61.
40. Das A, Guyton MK, Matzelle DD, Ray SK, Banik NL. Time-dependent increases in protease activities for neuronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis. J Neurosci Res. 2008;86:2992-3001.
41. Pender MP, Rist MJ. Apoptosis of inflammatory cells in immune control of the nervous system: role of glia. Glia. 2001; 36:137-44.
42. Bonetti B, Pohl J, Gao Y-L, Raine CS. Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J Immunol. 1997;159:5733-41.
43. Cudrici C, Niculescu T, Niculescu F, Shin ML, Rus H. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: protection of oligodendrocytes from apoptosis by complement. J Rehabil Res Dev. 2006;43:123-32.
44. Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu S, Singh A, et al. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival. J Neuroimmunol. 2009;213:3-11.
45. Dowling P, Husar W, Menonna J, Donnenfeld H, Cook S, Sidhu M. Cell death and birth in multiple sclerosis brain. J Neurol Sci. 1997;149:1-11.
46. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol. 2004;55:458-68.
47. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH. T-cell-and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain. 2001;124:2203-14.
48. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8:205-16.
49. Zalewska T, Ziemka-Nalecz M, Sarnowska A, Doma ska-Janik K. Transient forebrain ischemia modulates signal transduction from extracellular matrix in gerbil hippocampus. Brain Res. 2003; 977:62-9.
50. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR, et al. Matrix metalloproteinase-9/ gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol. 2008;9:34-46.
51. Kieseier BC, Kiefer R, Clements JM, Miller K, Wells GMA, Schweitzer T, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain. 1998;121:159-66.
52. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol. 1998;152:729-41.
53. Rosenberg GA. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist. 2002;8:586-95.
54. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci. 2005;25:6401-8.
55. Lu A, Clark JF, Broderick JP, Pyne-Geithman GJ, Wagner KR, Ran R, et al. Reperfusion activates metalloproteinases that contribute to neurovascular injury. Exp Neurol. 2008;210:549-59.
56. McColl BW, Rothwell NJ, Allan SM. Systemic inflammation alters the kinetics of cerebrovascular tight junction disruption after experimental stroke in mice. J Neurosci. 2008;28:9451-62.
57. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004;113:1447-55.
58. Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress. J Neuropathol Exp Neurol. 2010;69:801-16.
59. Louboutin JP, Reyes BA, Agrawal L, Van Bockstaele EJ, Strayer DS. HIV-1 gp120 upregulates matrix metalloproteinases and their inhibitors in a rat model of HIV encephalopathy. Eur J Neurosci. 2011;34:2015-23.
60. Wang GM, Guo QM, Hossain M, Fazio V, Zeynalov E, Janigro D, et al. Bone marrow-derived cells are the major source of MMP-9 contributing to blood-brain barrier dysfunction and infarct formation after ischemic stroke in mice. Brain Res. 2009;1294:183-92.
61. Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Neuroscience. 2009;158:1122-32.
62. Hagg T, Muir D, Engvall E, Varon S, Manthorpe M. Laminin antigens in rat CNS: distribution and changes upon brain injury. Neuron. 1989;3:721-32.
63. Murtomaki S, Trekner E, Wright J, Saksela O, Liesi P. Increased proteolytic activity of the granule neurons may contribute to neuronal death in the weaver mouse cerebellum. Dev Biol. 1995;168:635-48.
64. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997;91:917-25.
65. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci. 1997;17:543-52.
66. Brea D, Sobrino T, Ramos-Cabrer P, Castillo J. Inflammatory and neuroimmunomodulatory changes in acute cerebral ischemia. Cerebrovasc Dis. 2009;27(suppl 1):48-64.
67. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology. 2008;55:310-8.
68. Ridder DA, Schwaninger M. NF-kB signaling in cerebral ischemia. Neuroscience. 2009;158:995-1006.
69. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol. 2001;69:851-9.
70. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Micro-vascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-6.
71. Gurney KJ, Estrada EY, Rosenberg GA. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis. 2006;23:87-96